Editor - Dr. Shamim Ahmad | Augusta University | 21455
ISSN: 2168-9652

Biochemistry & Physiology: Open Access
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google scholar citation report
Citations : 688

Biochemistry & Physiology: Open Access received 688 citations as per google scholar report

Indexed In
  • CAS Source Index (CASSI)
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • Ulrich's Periodicals Directory
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • Scholarsteer
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Euro Pub
Share This Page

Dr. Shamim Ahmad

Dr. Shamim Ahmad
Shamim Ahmad
Cancer Center
Augusta University
Augusta, GA


Dr. Ahmad has extensive research experience in the field of Immunology, Biochemistry and cell signaling. The broad aim of his research is examination of cellular and molecular mechanisms differentially regulating the signaling of T cell subset signaling, function and survival. The aim of in depth examination of these signaling pathways is the development of strategies to selectively manipulate specific subsets to enhance the efficacy of immune therapies. Phosphoinositide 3-kinase (PI3K)-Akt signaling is important for the differentiation, proliferation, and survival of a variety of cells, including immune cells. Dr. Shamim Ahmad evaluated the anti-tumor efficacy of combinational immunotherapy based on model vaccine and PI3K isoform specific inhibitor. He demonstrates that this treatment leads to a profound inhibition of tumor growth. He showed that the potent therapeutic efficacy of treatment is mediated by i) enhancing number of the effector T cells infiltrating into the tumor that is facilitated and ii) the decrease Tregs. Thus, he provides a promising and translatable strategy that can enhance the overall efficacy of cancer immunotherapy.

Research Interest

His research is focused on development of combinational cancer immunotherapies, immune corrective strategies and investigation of cellular and molecular mechanisms involved in tumor-mediated immune suppression, and development of strategies to overcome that suppression.